CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target MaintainedTip Ranks·Aug 12 at 05:36 AMCRVO-0.77%
Analyst Maintains Buy on CervoMed, Cuts Target to $12 Amid Updated Launch Assumptions but Sees $3B Peak Sales PotentialTip Ranks·Aug 10 at 03:45 PMCRVO-0.77%
CervoMed | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 0Earnings Watch·Aug 10 at 03:09 PMCRVO-0.77%
Cervomed Q2 FY26 net loss widens 5% to $6.57 million; revenue turns to nonePUBT·Aug 7 at 03:28 PMCRVO-0.77%
CervoMed joins Canaccord Genuity Growth Conference fireside chat on neflamapimod progressPUBT·Aug 5 at 06:31 AMCRVO-0.77%
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) | CRVO Stock NewsStockTitan·Aug 3 at 08:15 PMCRVO-0.77%
CervoMed reports new Phase 2b data supporting neflamapimod 50 mg TID dose for planned DLB Phase 3 trialPUBT·Jul 14 at 06:35 AMCRVO-0.77%
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)Unusual Whales·Jul 14 at 06:31 AMCRVO-0.77%
CervoMed completes enrollment in Phase 2a neflamapimod trial for nonfluent PPAPUBT·Jul 9 at 06:34 AMCRVO-0.77%
